Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases, with a particular emphasis on autoimmune kidney disorders such as immunoglobulin A nephropathy (IgAN). The VERA news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow key clinical, regulatory, and corporate developments affecting the stock.
News about Vera Therapeutics frequently centers on its lead product candidate, atacicept, an investigational fusion protein targeting BAFF and APRIL. Recent announcements include submission and U.S. FDA Priority Review of a Biologics License Application for atacicept in adults with IgAN, supported by data from the ORIGIN Phase 2b and ORIGIN 3 Phase 3 trials. The company has highlighted statistically significant and clinically meaningful reductions in proteinuria and a safety profile described as comparable to placebo, as well as presentations at major scientific meetings and publication of trial results in The New England Journal of Medicine.
Investors and followers of VERA stock can also expect news on pipeline expansion and broader immunology programs. Vera Therapeutics reports ongoing evaluation of atacicept in expanded IgAN populations and other autoimmune kidney diseases, along with development of VT-109, a next-generation BAFF/APRIL-targeting fusion protein licensed from Stanford University, and MAU868, a monoclonal antibody designed to neutralize BK virus infection in kidney transplant recipients.
In addition, the news flow includes capital markets and corporate updates, such as underwritten public offerings of Class A common stock, at-the-market sales agreements, inducement equity grants under the company’s 2024 Inducement Plan, and changes in board composition or executive roles disclosed via Form 8-K. Vera Therapeutics also announces participation in healthcare and investor conferences, where its management team presents clinical data and corporate strategy.
By reviewing the VERA news page regularly, readers can track how clinical milestones, regulatory decisions, financing activities, and governance changes may relate to Vera Therapeutics’ development programs and its position as a late clinical-stage biotech issuer.
Vera Therapeutics (Nasdaq: VERA) will host an investor call and webcast on November 6, 2025 at 4:30 PM ET to review data from the ORIGIN Phase 3 trial of atacicept for IgA nephropathy (IgAN) presented at the morning plenary of ASN Kidney Week 2025.
Management will be joined by Jonathan Barratt, MD, PhD, FRCP and Richard Lafayette, MD, FACP. A live Q&A will follow. The webcast replay will be available for 90 days via the company’s Investor Calendar. Registration is required.
Vera Therapeutics (Nasdaq: VERA) announced that data from the Phase 3 ORIGIN trial of atacicept in IgA nephropathy (IgAN) will be presented as a featured late-breaking oral presentation in the Opening Plenary at ASN Kidney Week 2025 in Houston.
The oral presentation (Abstract TH-OR083) will be delivered by Richard Lafayette, MD on Thursday, November 6, 2025 from 9:02 AM–9:14 AM CST in Hall A. Two informational posters (INFO12-TH and INFO13-TH) on ORIGIN Extend and PIONEER will be available the same day from 10:00 AM–12:00 PM CST in the Exhibit Hall.
Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards granted by its Compensation Committee on October 6, 2025 to 21 new employees under the 2024 Inducement Plan.
The grants consist of 135,100 non‑qualified stock options and 70,775 restricted stock units (RSUs). Each option has an exercise price of $30.94, equal to Vera Therapeutics’ closing price on October 6, 2025. Options vest over four years with 25% after one year and monthly vesting over the following 36 months. RSUs vest 25% on each anniversary beginning November 20, 2025, over four years. Awards are subject to the Inducement Plan and individual award agreements and to continued service through vesting dates.
Vera Therapeutics (Nasdaq: VERA) announced inducement grants to eight new employees under its 2024 Inducement Plan. The grants include non-qualified stock options to purchase 85,000 shares of Class A common stock at $21.90 per share and restricted stock units (RSUs) for 45,250 shares.
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting from either August 20 or November 20, 2025. All grants are subject to continued employment with Vera.
Vera Therapeutics (NASDAQ: VERA), a late clinical-stage biotechnology company focused on immunological disease treatments, has announced its participation in two upcoming investor conferences in New York.
The company will participate in the Cantor Global Healthcare Conference on September 4, 2025, at 9:10am ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 5:35pm ET. Both events will feature fireside chats and one-on-one meetings with management.
A webcast replay will be accessible for 90 days through the company's website.
Vera Therapeutics (Nasdaq: VERA) announced the granting of inducement awards to eight new employees under its 2024 Inducement Plan. The awards, approved by the Compensation Committee, include non-qualified stock options for 99,000 shares and restricted stock units (RSUs) for 48,200 shares of Class A common stock.
The stock options, with an exercise price of $20.45, will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest in 25% increments annually over four years, starting August 20, 2025, contingent on continued employment.
[]Vera Therapeutics (Nasdaq: VERA) reported significant progress in Q2 2025, highlighted by positive results from their pivotal ORIGIN 3 trial for atacicept in IgA Nephropathy (IgAN) treatment. The trial achieved its primary endpoint with a 42% reduction in UPCR compared to placebo (p<0.0001), and participants showed a 46% reduction in proteinuria from baseline.
The company plans to submit a Biologics License Application (BLA) for atacicept to the FDA in Q4 2025, targeting commercial launch in 2026. Vera also initiated the PIONEER trial to evaluate atacicept in expanded patient populations. Financially, Vera secured a $500 million credit facility with Oxford Finance LLC and reported $556.8 million in cash and equivalents, ensuring funding through potential commercial launch.
Vera Therapeutics (Nasdaq: VERA) announced inducement grants to fifteen new employees under its Inducement Plan, approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The grants include non-qualified stock options to purchase 133,500 shares of Class A common stock at $24.00 per share and restricted stock units (RSUs) for 73,695 shares. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest 25% annually over four years starting August 20, 2025.